Effect of QUiPP prediction algorithm on treatment decisions in women with a previous preterm birth: a prospective cohort study. by Goodfellow, Laura et al.
A
cc
ep
te
d
 A
rt
ic
le
 
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1111/1471-0528.15886 
This article is protected by copyright. All rights reserved. 
DR. LAURA  GOODFELLOW (Orcid ID : 0000-0002-8111-5007) 
 
Article type      : main research article 
 
Effect of QUiPP prediction algorithm on treatment 
decisions in women with a previous preterm birth: a 
prospective cohort study 
Shortened running title: QUiPP treatment decisions 
Authors: 
Laura Goodfellow*, University of Liverpool and Liverpool Women’s Hospital, members of 
Liverpool Health Partners 
Angharad Care, University of Liverpool and Liverpool Women’s Hospital, members of 
Liverpool Health Partners 
Andrew Sharp, University of Liverpool and Liverpool Women’s Hospital, members of 
Liverpool Health Partners 
Jelena Ivandic, University of Liverpool and Liverpool Women’s Hospital, members of 
Liverpool Health Partners 
Borna Poljak, Liverpool Women’s Hospital, member of Liverpool Health Partners 
Devender Roberts, Liverpool Women’s Hospital, member of Liverpool Health Partners 
A
cc
ep
te
d
 A
rt
ic
le
 
This article is protected by copyright. All rights reserved. 
Zarko Alfirevic,  University of Liverpool and Liverpool Women’s Hospital, members of 
Liverpool Health Partners 
*Corresponding author. Address: University Department, Liverpool Women’s Hospital, 
Crown Street, Liverpool, L8 7SS. Tel: 0151 7959557. Fax: 0151 795 9599 email: 
l.goodfellow@liverpool.ac.uk 
Abstract  
Objective 
The QUiPP algorithm combines cervical length, quantitative fetal fibronectin (qfFN) and 
medical history to quantify risk of preterm birth. We assessed the utility of QUiPP to inform 
preterm birth prevention treatment decisions. 
Design 
A prospective cohort study with a subsequent impact assessment using the QUiPP risk of 
birth before 34 weeks gestation. 
Setting 
A UK tertiary referral hospital 
Sample 
119 women with previous spontaneous preterm birth (sPTB) or preterm premature rupture 
of membranes (PPROM) before 34 weeks gestation. 
Methods 
Cervical length and qfFN were measured at 19+0 - 23+0 weeks gestation. Clinical 
management was based on history and cervical length. After birth, clinicians were unblinded 
to qfFN results and QUiPP analysis was undertaken. 
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Main outcome measures 
Predictive statistics of QUiPP algorithm using 10% risk of sPTB before 34+0 weeks as 
treatment threshold. 
Results 
Fifteen of 119 women (13%) had PPROM or sPTB before 34 weeks. Of these 53% (8/15) had 
QUiPP risk of sPTB before 34+0 weeks above 10%. Applying this treatment threshold in 
practice would have doubled our treatment rate (20% vs 42%). QUIPP threshold of 10% had 
positive likelihood ratio (LR) of 1.3 (95% CI 0.76-2.18), and negative LR of 0.8 (95% CI 0.45-
1.40) for predicting sPTB before 34+0 weeks.  
Conclusions 
Use of the QUiPP algorithm in this population may lead to substantial increase in 
interventions without evidence that currently available treatment options are beneficial for 
this particular group.   
Funding 
Harris-Wellbeing Preterm Birth Research Centre.  
Keywords 
QUiPP; Preterm birth prevention treatment; Cervical length; Quantitative fetal fibronectin 
Tweetable abstract  
Independent study finds that the QUiPP algorithm could lead to substantial increases in 
treatment without evidence of benefit.  
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Introduction  
In order to reduce the risk of preterm birth national guidelines often recommend targeted 
antenatal treatment based on obstetric history and a defined cervical length measurement, 
commonly <25mm.1–3 However, cervical length screening alone does not detect all women 
who go on to have a preterm birth. Care et al have shown that in women with previous 
spontaneous preterm birth (sPTB) before 34 weeks or preterm premature rupture of 
membranes (PPROM) 9% of women will have another birth  before 34 weeks gestation 
despite a cervical length >25mm at 20-25 weeks gestation.4 There is, therefore, an urgent 
need to identify alternative methods in order to avoid these ‘false negative’ assessments, so 
that preterm birth prevention treatment can be considered.  
 
The QUiPP application (App), developed by Shennan et al. is a way of quantifying a woman’s 
risk of preterm birth and is a user-friendly algorithm, available free of charge on the internet 
and as a mobile application.5  The current (October 2018) version of the App is based on 
1803 asymptomatic women reviewed in preterm birth prevention clinics in London.6 It can 
be applied from 18 weeks gestation onwards by inputting the following variables: obstetric 
history; history of cervical surgery; cervical length; quantitative fetal fibronectin (qfFN); 
current gestation; number of fetuses. The clinician is then presented with the probability of 
birth within one, two and four weeks, and prior to 30, 34 and 37 weeks gestation. There is 
currently no proposed protocol on how to use this information.  
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Preterm birth prevention clinics are becoming increasingly common in UK practice. As 
recently as 2012 the majority of preterm birth prevention clinics were researcher led, but a 
2017 survey of UK practice7 showed that the majority are now led by NHS clinicians. This 
survey showed that the QUiPP app was already being used to guide treatment decisions in 
6% of UK hospitals (6/94).7 This suggests an urgent need to assess and discuss the impact of 
this algorithm on preterm birth prevention treatment. 
 
We therefore performed a prospective, blinded, analysis of the use of the QUiPP app in our 
preterm birth prevention clinic, to assess the potential impact on the management of 
women at high risk of preterm birth. This study aimed to involve patients in the study design 
to optimise participant engagegment with the study. 
Method 
Women with a singleton pregnancy and a history of sPTB or PPROM <34 weeks or late 
miscarriage (16+0-23+6 weeks gestation) who attended our preterm birth prevention clinic 
were invited to take part in a biomarkers of preterm birth study. Participants were recruited 
from June 2015 until December 2017.  
 
For the purposes of this paper we have combined the data collected at the 19+0-23+0 weeks 
study visit for vaginal quantitative fetal fibronectin (qfFN), cervical length and past obstetric 
history. The qfFN swabs were processed by laboratory technicians, and both clinicians and 
participants were blinded to the qfFN result until all women in the study had given birth. 
Clinical management was based on cervical length, previous history and clinician and patient 
preference, as is normal practice in our clinic. Participants with a cervical length under the 
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3rd centile for their gestation8 were offered preterm birth prevention treatment with vaginal 
progesterone, cervical cerclage or Arabin cervical pessary. Information was collected about 
initiation of preterm birth prevention treatment for the remainder of the pregnancy. 
 
Women who had already received preterm birth prevention treatment prior to their study 
visit were not recruited. We felt that if treatment had already been initiated, it is unlikely 
that the ‘negative’ QUiPP risk assessment would have been sufficiently reassuring to prompt 
discontinuation of the preventative treatments. 
 
All women were asymptomatic of preterm birth at the time of participation. Women were 
included even if they had had recent vaginal bleeding, as this has been shown to only have a 
small detrimental effect on the prediction of preterm birth by qfFN.9 Participants were not 
recruited if they reported intercourse in the previous 48 hours, as this reduces the reliability 
of qfFN.10 The speculum examination to obtain cervico vaginal fluid for qfFN analysis was 
performed prior to ultrasound and/or digital assessment of the cervix. 
 
The qfFN swabs were analysed by the Rapid fFN® 10Q System (HOLOGIC, USA). Participant’s 
obstetric history, cervical length and treatment decisions were entered onto our study 
database. Once the qfFN result was available these observations were then entered into the 
QUiPP application to obtain the participant’s risk of birth prior to 34 weeks gestation. The 
study team corresponded with the QUiPP authors in order to apply the defintions of 
previous spontaneous miscarriage/PPROM/sPTB consistently with the original study.  
Pregnancies with PPROM that delivered spontaneously before 24+0 weeks gestation were 
classified as spontaneous miscarriage, and if they spontaneously laboured or developed 
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chorioamnionitis before 37+0 weeks gestation they were classified as sPTB.  The PPROM 
label was applied to previous pregnancies that had PPROM before 37+0 week and with 
delivery after 37 weeks, or indicated delivery sooner for non-infectious indications. 
 
After birth delivery two clinicians (AC and LG) reviewed the case notes and classified the 
pregnancies as either: PPROM or sPTB <34 weeks, birth ≥ 34 weeks, or iatrogenic preterm 
birth <34 weeks. Participants with iatrogenic preterm birth before 34 weeks were excluded 
from the analysis. For women who delivered elsewhere the participant and/or the 
delivering hospital were contacted to obtain the birth outcome details. 
 
The primary outcome of PPROM or sPTB before 34+0 weeks gestation was chosen to reflect 
the gestational threshold used in QUIPP. In addition, the incidence of iatrogenic preterm 
birth rises significantly after 34 weeks in this high risk cohort. We chose to combine the 
outcome of spontaneous birth <34 weeks with PPROM < 34 weeks, as once the membranes 
are ruptured at early gestations any ongoing pregnancy remains vulnerable to serious 
complications including chorioamnionitis, cord prolapse and placental abruption.  
 
In order to analyse the utility of the QUiPP app for the prediction of preterm birth in our 
cohort, it was necessary to apply a ‘treatment threshold’ to the QUiPP results. The initial 
publication describing the algorithm used a ‘positive test’ threshold of 10% for birth within 
the timeframe of interest.11 We therefore started our analysis with a ‘treatment threshold’ 
of 10%, and assessed whether we could further optimise this threshold for the benefit of 
our population. 
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We considered the core outcome set for preterm birth.12 We have reported on prelabour 
rupture of membranes and gestational age at birth. The remainder of the set is not relevant 
to this observational cohort study as these outcomes are not evaluated in the QUIPP app. 
 
The prospective cohort study was funded as part of a charitable donation that founded the 
Harris-Wellbeing Preterm Birth Research Centre, University of Liverpool. This covered 
administrative costs, the quantitative fetal fibronectin tests, salary for AC, study support 
costs for AC and LG.  
Patient involvement 
The Harris-Wellbeing Preterm Birth Research Centre Patient and Public Involvement group 
were formed in 2015 and this group helped guide the research team on the practicalities of 
recruitment. This included discussing the qfFN testing process, and the blinding of the result 
with participants.  
 
Results 
The study population consisted of 123 women. There were four exclusions: two women 
were excluded because of intrauterine deaths at 20+4 and 30+0 weeks gestation; one woman 
was delivered for severe maternal disease at 31+4; and one woman was induced for 
maternal anxiety at 33+6. This gave a population of 119 women suitable for analysis. Birth 
outcome details were available for all participants. Table 1 shows their demographic details, 
and the cervical length and qfFN measurements.  
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Overall, 15 women (13%) had either spontaneous birth or PPROM before 34+0 weeks and 24 
women (20%) received treatment because of short cervix, either at the study visit (7 
women, 6%) or subsequently (17 women, 14%). Figure S1 details the preterm birth 
prevention treatment received and pregnancy outcomes for all participants. 
 
If QUiPP treatment threshold had been set at 10%, then the treatment rate would have 
more than doubled to 42% (51/119). Figure 1 shows the QUiPP risk of preterm birth <34 
weeks, and how a treatment threshold of 10% relates to the gestation of PPROM or birth. 
Forty three of 51 QUIPP positive women (84%) were still pregnant at 34 weeks (false 
positive rate). However 16 of these 43 women (37%) did receive preterm birth prevention 
treatment, as shown by the crosses (x) in Figure 1. If we were to assume that all women 
who were treated would have had a sPTB or PPROM <34+0 weeks gestation then the false 
positive rate would be reduced to 53% (27/51).  Twenty seven of the 51 QUiPP positive 
women (52%) had no preterm birth prevention treatment because their cervical length 
remained within normal range. Seven out of 68 QUIPP negative women (10%) had PPROM 
or sPTB <34 weeks (false negative rate). Table 2 shows the predictive statistics for QUIPP 
with a treatment threshold of 10%. Table S1 shows the adjusted predictive statistics for 
QUiPP with a treatment threshold of 10% if all women in the current study who received 
preterm birth prevention treatment had sPTB or PPROM <34+0 weeks gestation.  
 
In order to assess whether an alternative treatment threshold would have improved the 
utility of the QUiPP app we calculated the positive and negative likelihood ratios (LR + and 
LR-) for PPROM or sPTB <34 weeks over a range of clinically useful treatment thresholds. As 
shown in Figure 2 the best accuracy was achieved with an 8% threshold which gave a  LR +ve 
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of 1.5 and LR -ve of 0.4. This would give a treatment rate of 55% (66/119), with a true 
positive rate of 80% (12/15), false positive rate of  81% (54/66) and false negative rate of 6% 
(3/53). 
 
Our validation cohort had some dissimilarities to the QUiPP application development 
population which may explain the different performance of the algorithm. We limited our 
analysis to women with previous preterm birth; the QUiPP algorithm also includes women 
with previous cervical surgery as their only preterm birth risk factor. The algorithm is 
updated regularly by the team at Kings Health Partners and demographic data is not 
available for all participants used for version 2.0. 5 Compared to the initially published 
iteration of the QUiPP algorirthm our study participants: were slightly younger (mean age 30 
years vs 33 years); had a higher rate of a cervical length under 25mm prior to 30 weeks 
gestation (20% vs 15%); and had a higher rate of white ethnic origin (96% vs 56%).5 
 
The patient and public involvement group helped with the development of our participant 
information leaflet. They found the process of blinding of the fibronectin results to the 
participants and clinicians acceptable because the QUiPP algorithm was not yet in routine 
clinical practice. Patients have not yet been involved in the dissemination of results.  
Discussion  
Main Findings 
In our high risk cohort, application of the QUiPP algorithm would have directed treatment to 
eight women (7% of the cohort) who were not treated using current care pathways and 
went on to have PPROM or sPTB < 34 weeks. This assumes application of the algorithm 
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between 19 and 23 weeks of gestation and a treatment threshold of QUiPP risk of PTB <34 
weeks of >10%.  However, our data suggest that this strategy may also lead to unnecessary 
treatment in a relatively high proportion of women. In our cohort the rate of treatment 
would be more than doubled if cervical length was replaced by QUIPP risk of preterm birth 
>10% as a trigger for treatment (20% vs 42%). Even with nearly half of women treated, 46% 
of women who had PPROM or sPTB <34 weeks would remain untreated. Changing the 
treatment threshold within clinically acceptable limits did little to improve this.  
 
If we were to assume that the women treated in the current study would have all had a 
preterm birth <34+0 weeks gestation without treatment then this does improve the 
predictive statistics of the QUiPP algorithm (Table S1). However the results are still within 
the confidence errors for our initial predictive statistics (Table 2), and still represent an 
increase in treatment of 27/119 women (23%). 
 
The Harris patient and public involvement group welcomed this study and were very helpful 
in facilitating the practicalities of recruitement. There were no negative effects to this. 
Patients have not yet been involved in the analysis or interpretation of the results. 
Strengths 
This is the first study to analyse the application of the QUiPP algorithm on preterm birth 
prevention treatment decisions. The QUiPP app is already being adopted in clinical 
practice,7 and so this is a timely assessment of the impact of this change.  
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Limitations 
All women in this cohort received PTB prevention treatment based on cervical length, as is 
our standard clinical practice. This means that all women with a short cervix received 
treatment, and in doing so may have falsely reduced the predictive power of cervical length 
alone in predicting PPROM/sPTB. Conversely, clinicians and participants were blinded to the 
qfFN and so treatment was not offered to women with a normal CL and high QUiPP 
risk/qfFN, and their preterm birth risk was therefore not affected by treatment. This also 
means that direct comparison between predictive power of cervical length alone and QUiPP 
risk was not possible. 
 
A second limitation is that the qfFN measurement was only performed on a single study visit 
for each participant. Using our current care pathway, 13% of participants received PTB 
prevention treatment because of short cervix detected at the subsequent visits. We are 
unable to assess the impact that QUiPP would have had on treatment rate if used later in 
the pregnancy. 
 
The QUiPP algorithm has been developed using women based in and around London, UK. 6 
Ultimately it is hoped that this tool can be modified for different populations and developed 
with additional predictors to improve its performance. 
Interpretation 
Use of the QUiPP algorithm in this population would increase our rate of treatment to 42% 
from 20%, and allow us to target 8/15 (53%) of women who went on to have PPROM or 
sPTB <34 weeks.  It could be argued that a relatively high treatment rate is acceptable for 
high risk population in order to minimise the risk of severe complications of extreme 
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prematurity. The currently available preterm birth prevention treatments of cervical 
cerclage, Arabin pessary and vaginal progesterone are relatively well tolerated and have low 
complication rates. 13 Women who have had a previous preterm birth are often extremely 
motivated to achieve a term birth, and so there is the pressure to offer and accept 
treatments to prevent sPTB or PPROM recurrence.  However, we do not currently have 
evidence for a preterm birth prevention treatment based on QUiPP risk of preterm birth. 
 
A strength of the QUiPP algorithm is that it provides women and clinicians with a 
personalised risk of preterm birth. This can then be interpreted by the clinician, patient and 
family to make individual treatment decisions. On an individual level this is a goal of 
preterm birth prevention. In order to reach the goal and appropriately counsel a woman 
about her risk in a range of situations it would be ideal if a treatment threshold could be 
agreed, and then an intervention tested at that threshold for its ability to prevent preterm 
birth. Unfortunately the process of this analysis could be taking away the individualised 
nature of the risk scoring system. 
 
Until such time when we have a better performing predictive tool for preterm birth, an 
alternative strategy is to offer prevention treatment to all women with a previous PPROM or 
sPTB.  The American College of Obstetricians recommends weekly injections of 17 alpha-
hydroxyprogesterone caproate to this group. 14  Vaginal admistration of natural 
progesterone could be an alternative strategy but the Cochrane review and OPPTIMUM 
study did not find evidence for reduction in PTB risk with this strategy. 15,16  It is hoped that 
soon to be published individual patient data analysis by the EPPPIC group will provide 
definitive evidence in this respect.17  
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Conclusion 
The QUiPP algorithm is a novel tool in the field of preterm birth facilitating individualised 
prediction, and a welcome advance in personalised care. Our analysis suggests that the 
algorithm would more than double the preterm birth prevention treatment rate, and 
accordingly increase the number of women who receive treatment both appropriately and 
inappropriately. Future research should seek to refine individualised risk assessment and 
the utility of PTB prevention treatments based on it.  
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Figure legends 
Figure 1 
Gestational age at birth, or PPROM (which ever happened first) for 119 women and their 
QUiPP risk of birth <34 weeks calculated at 19+0 - 23+0 weeks gestation. Vertical dashed lines 
represent proposed treatment threshold (10%) and horizontal dashed lines represent 34+0  
weeks gestation of event of birth or PPROM. Dots (●) represent participants who did not 
have preterm birth prevention treatment. Crosses (x) represent participants who did have 
preterm birth prevention treatment, either at the study visit or at a subsequent visit 
Figure 2 
Chart to show alteration in QUiPP likelihood ratio for prediction of PPROM or sPTB under 34 
weeks by variation in QUiPP risk of birth under 34 weeks used as 'positive test' threshold 
Figure S1 
Diagram to show preterm birth prevention interventions and pregnancy outcomes for study 
participants 
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Table 1: Demographic data, fetal fibronectin and cervical length data for our cohort . 
PPROM, preterm prelabour rupture of membranes. Results in brackets are percentages or 
standard deviation*. 
     Value 
   (N=119) 
Age* (years)  30.1 (4.6) 
Ethnicity White  114 (95.8) 
 Black  2 (1.7) 
 Asian  0 (0) 
 Not stated  3 (2.5) 
Body mass index <20 kg/m2  12 (10.1) 
 20-24.9 kg/m2 46 (38.7) 
 25-29.9 kg/m2 30 (25.2) 
 ≥30 kg/m2  30 (25.2) 
 Unknown  1  (0.8) 
Smoking No  92 (77.3) 
 Cigarettes/day   
  0-5 12 (10.1) 
  6-10 10 (8.4) 
  11-20 2 (1.7) 
  >20 2 (1.7) 
 Unknown  1 (0.8) 
Risk factors Previous    
  sPTB 87 (73.1) 
  PPROM 5 (4.2) 
  Late miscarriage 21 (17.6) 
  sPTB and late 
miscarriage 
6 (5.0) 
     
Characteristic at 19+0-23+0 weeks gestation  
Quantitative fetal fibronectin (qfFN) <10ng/ml 81 (68.1) 
  10-19.9ng/ml 10 (8.4) 
  20-49.9ng/ml 13 (10.9) 
  50-99.9ng/ml 6 (5.0) 
  100-199.9ng/ml 4 (3.4) 
  ≥200ng/ml 5 (4.2) 
Cervical length  <15mm 1 (0.8) 
  15-24.9mm 6 (5.0) 
  ≥25 mm 112 (94.1) 
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Table 2: Predictive Statistics for PPROM or sPTB<34 weeks using the QUiPP algorithm risk of birth 
under 34 weeks over 10% as the treatment threshold. 
 
 
 
 
 
 
 
 
 
 
  
 sPTB or PPROM <34 
weeks (n) 
Birth after 34 
weeks (n) 
QUIPP >10% 8 43 
QUIPP <10% 7 61 
 
 
  
Parameter 
Predictive statistics 
for PPROM or sPTB 
<34 weeks 
95% Confidence 
Interval 
Sensitivity 0.53 0.28-0.79 
Specificity 0.59 0.49-0.68 
PPV 0.16 0.06-0.26 
NPV  0.90 0.82-0.97 
LR +ve 1.29 0.76-2.18 
LR-ve 0.80 0.45-1.40 
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Figure 1: Gestational age at birth, or PPROM (which ever happened first) for 119 women and their QUiPP risk of birth <34 
weeks calculated at 19
+0 
- 23
+0
 weeks gestation. Vertical dashed lines represent proposed treatment threshold (10%) and 
horizontal dashed lines represent 34
+0
 weeks gestation of event of birth or PPROM. Dots (●) represent participants who did 
not have preterm birth prevention treatment. Crosses (x) represent participants who did have preterm birth prevention 
treatment, either at the study visit or at a subsequent visit.  
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